Forest accused of fraudulent US paediatric promotion of Celexa
This article was originally published in Scrip
Executive Summary
The US government has accused Forest Laboratories of marketing its SSRI antidepressants Celexa (citalopram) and Lexapro (escitalopram) for unapproved paediatric use and for paying kickbacks to induce physicians to prescribe the products, in violation of federal anti-kickback laws, according to the Department of Justice.